Prime Editor 3 Mediated Beta-Thalassemia Mutations of the

Haokun Zhang, Qinlinglan Zhou, Hongyan Chen, Daru Lu

Open access · goldAbstract read

In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

1.0field-weighted citation impact, top 27% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

Advances in β-Thalassemia Gene Therapy: CRISPR/Cas Systems and Delivery Innovations.Cells · 2025
Review
Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype.Nature communications · 2023
Article
Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders.Frontiers in genome editing · 2022
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Haokun ZhangState Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai 200438, China.ORCID 0000-0003-2466-949X

Qinlinglan ZhouState Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai 200438, China.ORCID 0000-0001-6323-6625

Hongyan ChenState Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai 200438, China.

Daru LuState Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai 200438, China.

Fudan University · CN

Funding

China Postdoctoral Science Foundation funded project 2019M651353Science and Technology Commission of Shanghai Municipality 19YF1403500

6 · The paper itself

Abstract

Recently developed Prime Editor 3 (PE3) has been implemented to induce genome editing in various cell types but has not been proven in human hematopoietic stem and progenitor cells. Using PE3, we successfully installed the beta-thalassemia (beta-thal) mutations in the HBB gene in the erythroid progenitor cell line HUDEP-2. We inserted the

Indexed as

beta-ThalassemiaErythroid Precursor CellsGene EditingHemoglobinsalpha-Globinsbeta-GlobinsHumansMutationalpha-Globinsbeta-Globinshemoglobin BHemoglobinsbeta-thalassemia mutationgenome editingHUDEP-2 cellsprime editor 3the HBB gene

Identifiers

PMID35563395

DOI10.3390/ijms23095002

PMCPMC9099916

OpenAlexW4225259822

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.